Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
We have been looking forward to the release of CLiC technology. Fluid overload in dialysis patients is an important issue that needs to be addressed. I’m proud to support the introduction of a technological breakthrough that will allow nephrologists to have access to important data and make informed decisions that will directly impact the health and well-being of this chronically-ill population. Fresenius Renal Therapies is dedicated to working with nephrologists and dialysis clinicians in a continued effort to improve patient outcomes and overall quality of life.”
The CLiC device is designed to allow the health care professional to remove the maximum amount of fluid from the hemodialysis patient while preventing the common symptoms of dialysis such as nausea, cramping and vomiting, thus providing a more effective treatment.
“The CLiC device represents a significant step forward in the evolution of volume management,” said Frank Maddux, MD, Chief Medical Officer of FMCNA. “By assisting clinical staff in managing hemodialysis patients’ complex fluid and intravascular volume conditions, the CLiC will be a valuable tool for clinicians. Moreover, with the integration of the CLiC device into the 2008T machine, clinical staff can more quickly recognize a patient’s risk for low blood pressure during hemodialysis resulting from certain ultrafiltration and intravascular blood volume characteristics. Once the CLiC device alerts staff, they can pause ultrafiltration until the clinicians can assess the situation of their patient. This industry-leading device is a significant step forward in improving patients’ quality of life.”
For customers utilizing other 2008® series machines, the organization introduced, today, the Crit-Line® IV monitor, a stand-alone device providing access to patient profile information, including hematocrit, oxygen and percent change in intravascular blood
volume during treatment.
About Fresenius Medical Care North America
Fresenius Medical Care North America is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the country’s largest practice of hospitalist and post-acute providers, Fresenius Medical Care provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at www.fmcna.com. For information about Crit-Line Technology click here.